Development of anticancer agents targeting the wnt/β-catenin signaling

American Journal of Cancer Research

Volumn 5, Issue 8, 2015, Pages 2344-2360

  Zhang, Xiangqian ^a   Hao, Jijun ^b  

^a YAN'AN UNIVERSITY   (China)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Biologic agents; Cancer; Safety and clinic; Small molecules; Therapeutic; Wnt catenin signaling; catenin

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; BIOLOGICAL PRODUCT; CASEIN KINASE I INHIBITOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DISHEVELLED PROTEIN; E1A ASSOCIATED P300 PROTEIN; ENZYME INHIBITOR; J 01 017A; NSC 668036; PORCUPINE INHIBITOR; PRI 724; TANKYRASE INHIBITOR; UNCLASSIFIED DRUG; VANTICTUMAB; WNT PROTEIN;

ARTICLE; CARCINOGENESIS; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; WNT BETA CATENIN SIGNALING PATHWAY;

EID: 85006201221     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (117)

1. Nusse R and Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982; 31: 99-109.
2. Baker NE. Molecular cloning of sequences from wingless, a segment polarity gene in Drosophila: the spatial distribution of a transcript in embryos. EMBO J 1987; 6: 1765-1773.
3. Logan CY and Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004; 20: 781-810.
4. van Amerongen R and Nusse R. Towards an integrated view of Wnt signaling in development. Development 2009; 136: 3205-3214.
5. Alonso L and Fuchs E. Stem cells in the skin: waste not, Wnt not. Genes Dev 2003; 17: 1189-1200.
6. Pinto D and Clevers H. Wnt control of stem cells and differentiation in the intestinal epithelium. Exp Cell Res 2005; 306: 357-363.
7. Nemeth MJ, Mak KK, Yang Y and Bodine DM. beta-Catenin expression in the bone marrow microenvironment is required for long-term maintenance of primitive hematopoietic cells. Stem Cells 2009; 27: 1109-1119.
8. Reya T and Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434: 843-850.
9. Dees C and Distler JH. Canonical Wnt signalling as a key regulator of fibrogenesis - implications for targeted therapies? Exp Dermatol 2013; 22: 710-713.
10. Chilosi M, Poletti V, Zamo A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, Scarpa A, Murer B, Cancellieri A, Maestro R, Semenzato G and Doglioni C. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003; 162: 1495-1502.
11. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A and Perret C. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998; 95: 8847-8851.
12. Anastas JN and Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13: 11-26.
13. Berwick DC and Harvey K. The importance of Wnt signalling for neurodegeneration in Parkinson's disease. Biochem Soc Trans 2012; 40: 1123-1128.
14. Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol 2012; 4.
15. Klaus A and Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008; 8: 387-398.
16. Fagotto F. Looking beyond the Wnt pathway for the deep nature of beta-catenin. EMBO Rep 2013; 14: 422-433.
17. Miller RK, Hong JY, Munoz WA and McCrea PD. Beta-catenin versus the other armadillo catenins: assessing our current view of canonical Wnt signaling. Prog Mol Biol Transl Sci 2013; 116: 387-407.
18. MacDonald BT, Tamai K and He X. Wnt/betacatenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17: 9-26.
19. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X and He X. Control of betacatenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108: 837-847.
20. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66: 589-600.
21. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D, et al. Identification of FAP locus genes from chromosome 5q21. Science 1991; 253: 661-665.
22. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya J, Baba S and Hedge P. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991; 253: 665-669.
23. Rubinfeld B, Souza B, Albert I, Muller O, Chamberlain SH, Masiarz FR, Munemitsu S and Polakis P. Association of the APC gene product with beta-catenin. Science 1993; 262: 1731-1734.
24. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B and Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997; 275: 1784-1787.
25. Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK, Halling KC, Cunningham JM, Boardman LA, Qian C, Christensen E, Schmidt SS, Roche PC, Smith DI and Thibodeau SN. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet 2000; 26: 146-147.
26. Lammi L, Arte S, Somer M, Jarvinen H, Lahermo P, ThesleffI, Pirinen S and Nieminen P. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet 2004; 74: 1043-1050.
27. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-1790.
28. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E and Polakis P. Stabilization of betacatenin by genetic defects in melanoma cell lines. Science 1997; 275: 1790-1792.
29. Herr P, Hausmann G and Basler K. WNT secretion and signalling in human disease. Trends in Mol Med 2012; 18: 483-493.
30. Han ZG. Functional Genomic Studies: Insights into the Pathogenesis of Liver Cancer. Annual Rev Genomics Hum Genet 2012; 13: 171-205.
31. Sastre-Perona A and Santisteban P. Role of the wnt pathway in thyroid cancer. Front Endocrinol (Lausanne) 2012; 3: 31.
32. Gatcliffe TA, Monk BJ, Planutis K and Holcombe RF. Wnt signaling in ovarian tumorigenesis. Int J Gynecol Cancer 2008; 18: 954-962.
33. Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P, Chughtai S, Wallis Y, Matthews GM and Morton DG. The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Research 2004; 64: 883-888.
34. Lee AY, He B, You L, Dadfarmay S, Xu ZD, Mazieres J, Mikami I, McCormick F and Jablons DM. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 2004; 23: 6672-6676.
35. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG and Baylin SB. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36: 417-422.
36. Fukui T, Kondo M, Ito G, Maeda O, Sato N, Yoshioka H, Yokoi K, Ueda Y, Shimokata K and Sekido Y. Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene 2005; 24: 6323-6327.
37. Zou H, Molina JR, Harrington JJ, Osborn NK, Klatt KK, Romero Y, Burgart LJ and Ahlquist DA. Aberrant methylation of secreted frizzledrelated protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer 2005; 116: 584-591.
38. Rhee CS, Sen M, Lu DS, Wu C, Leoni L, Rubin J, Corr M and Carson DA. Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene 2002; 21: 6598-6605.
39. Milovanovic T, Planutis K, Nguyen A, Marsh JL, Lin F, Hope C and Holcombe RF. Expression of Wnt genes and frizzled 1 and 2 receptors in normal breast epithelium and infiltrating breast carcinoma. Int J Oncol 2004; 25: 1337-1342.
40. Okino K, Nagai H, Hatta M, Nagahata T, Yoneyama K, Ohta Y, Jin E, Kawanami O, Araki T and Emi M. Up-regulation and overproduction of DVL-1, the human counterpart of the Drosophila dishevelled gene, in cervical squamous cell carcinoma. Oncol Rep 2003; 10: 1219-1223.
41. Uematsu K, Kanazawa S, You L, He B, Xu Z, Li K, Peterlin BM, McCormick F and Jablons DM. Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Research 2003; 63: 4547-4551.
42. Uematsu K, He B, You L, Xu Z, McCormick F and Jablons DM. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene 2003; 22: 7218-7221.
43. Kuhnert F, Davis CR, Wang HT, Chu P, Lee M, Yuan J, Nusse R and Kuo CJ. Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc Natl Acad Sci U S A 2004; 101: 266-271.
44. Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C and Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998; 391: 357-362.
45. Liu CC, Prior J, Piwnica-Worms D and Bu GJ. LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci U S A 2010; 107: 5136-5141.
46. Lu WY, Liu CC, Thottassery JV, Bu GJ and Li YH. Mesd Is a Universal Inhibitor of Wnt Coreceptors LRP5 and LRP6 and Blocks Wnt/beta-Catenin Signaling in Cancer Cells. Biochemistry 2010; 49: 4635-4643.
47. DeAlmeida VI, Miao L, Ernst JA, Koeppen H, Polakis P and Rubinfeld B. The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Research 2007; 67: 5371-5379.
48. Li X, Placencio V, Iturregui JM, Uwamariya C, Sharif-Afshar AR, Koyama T, Hayward SW and Bhowmick NA. Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. Oncogene 2008; 27: 7118-7130.
49. Wei W, Chua MS, Grepper S and So SK. Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin. Mol Cancer 2011; 10: 16.
50. Pode-Shakked N, Harari-Steinberg O, Haberman-Ziv Y, Rom-Gross E, Bahar S, Omer D, Metsuyanim S, Buzhor E, Jacob-Hirsch J, Goldstein RS, Mark-Danieli M and Dekel B. Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target. Oncogene 2011; 30: 1664-1680.
51. Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L, Fischer M, Chaudhari A, Ji M, Kapoun AM, Lam A, Lazetic S, Ma S, Mitra S, Park IK, Pickell K, Sato A, Satyal S, Stroud M, Tran H, Yen WC, Lewicki J and Hoey T. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A 2012; 109: 11717-11722.
52. Grossmann TN, Yeh JTH, Bowman BR, Chu Q, Moellering RE and Verdine GL. Inhibition of oncogenic Wnt signaling through direct targeting of beta-catenin. Proc Natl Acad Sci U S A 2012; 109: 17942-17947.
53. Takada K, Zhu D, Bird GH, Sukhdeo K, Zhao JJ, Mani M, Lemieux M, Carrasco DE, Ryan J, Horst D, Fulciniti M, Munshi NC, Xu W, Kung AL, Shivdasani RA, Walensky LD and Carrasco DR. Targeted disruption of the BCL9/betacatenin complex inhibits oncogenic Wnt signaling. Sci Transl Med 2012; 4: 148ra117.
54. Sussman DJ, Klingensmith J, Salinas P, Adams PS, Nusse R and Perrimon N. Isolation and characterization of a mouse homolog of the Drosophila segment polarity gene dishevelled. Dev Biol 1994; 166: 73-86.
55. Semenov MV and Snyder M. Human dishevelled genes constitute a DHR-containing multigene family. Genomics 1997; 42: 302-310.
56. Klingensmith J, Yang Y, Axelrod JD, Beier DR, Perrimon N and Sussman DJ. Conservation of dishevelled structure and function between flies and mice: Isolation and characterization of Dvl2. Mech Dev 1996; 58: 15-26.
57. Pizzuti A, Amati F, Calabrese G, Mari A, Colosimo A, Silani V, Giardino L, Ratti A, Penso D, Calza L, Palka G, Scarlato G, Novelli G and Dallapiccola B. cDNA characterization and chromosomal mapping of two human homologues of the Drosophila dishevelled polarity gene. Hum Mol Genet 1996; 5: 953-958.
58. Tsang M, Lijam N, Yang Y, Beier DR, Wynshaw-Boris A and Sussman DJ. Isolation and characterization of mouse dishevelled-3. Dev Dyn 1996; 207: 253-262.
59. Wharton KA. Runnin' with the Dvl: Proteins that associate with Dsh/Dvl and their significance to Wnt signal transduction. Developmental Biology 2003; 253: 1-17.
60. Schwarz-Romond T, Fiedler M, Shibata N, Butler PJ, Kikuchi A, Higuchi Y and Bienz M. The DIX domain of Dishevelled confers Wnt signaling by dynamic polymerization. Nat Struct Mol Biol 2007; 14: 484-492.
61. Tauriello DV, Jordens I, Kirchner K, Slootstra JW, Kruitwagen T, Bouwman BA, Noutsou M, Rudiger SG, Schwamborn K, Schambony A and Maurice MM. Wnt/beta-catenin signaling requires interaction of the Dishevelled DEP domain and C terminus with a discontinuous motif in Frizzled. Proc Natl Acad Sci U S A 2012; 109: E812-820.
62. Simons M, Gault WJ, Gotthardt D, Rohatgi R, Klein TJ, Shao YM, Lee HJ, Wu AL, Fang YM, Satlin LM, Dow JT, Chen J, Zheng J, Boutros M and Mlodzik M. Electrochemical cues regulate assembly of the Frizzled/Dishevelled complex at the plasma membrane during planar epithelial polarization (vol 11, pg 286, 2009). Nature Cell Biology 2009; 11: 508-508.
63. Wong HC, Bourdelas A, Krauss A, Lee HJ, Shao Y, Wu D, Mlodzik M, Shi DL and Zheng J. Direct binding of the PDZ domain of Dishevelled to a conserved internal sequence in the C-terminal region of Frizzled. Mol Cell 2003; 12: 1251-1260.
64. Punchihewa C, Ferreira AM, Cassell R, Rodrigues P and Fujii N. Sequence requirement and subtype specificity in the high-affinity interaction between human frizzled and dishevelled proteins. Protein Science 2009; 18: 994-1002.
65. Zhang L, Gao X, Wen J, Ning Y and Chen YG. Dapper 1 antagonizes Wnt signaling by promoting dishevelled degradation. J Biol Chem 2006; 281: 8607-8612.
66. Chen H, Liu L, Ma B, Ma TM, Hou JJ, Xie GM, Wu W, Yang FQ and Chen YG. Protein kinase A-mediated 14-3-3 association impedes human Dapper1 to promote dishevelled degradation. J Biol Chem 2011; 286: 14870-14880.
67. Cheyette BN, Waxman JS, Miller JR, Takemaru KI, Sheldahl LC, Khlebtsova N, Fox EP, Earnest T and Moon RT. Dapper, a Dishevelledassociated antagonist of beta-catenin and JNK signaling, is required for notochord formation. Developmental Cell 2002; 2: 449-461.
68. Shan J, Shi DL, Wang J and Zheng J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 2005; 44: 15495-15503.
69. Shan J, Zhang X, Bao J, Cassell R and Zheng JJ. Synthesis of potent dishevelled PDZ domain inhibitors guided by virtual screening and NMR studies. Chem Biol Drug Des 2012; 79: 376-383.
70. Grandy D, Shan J, Zhang X, Rao S, Akunuru S, Li H, Zhang Y, Alpatov I, Zhang XA, Lang RA, Shi DL and Zheng JJ. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J Biol Chem 2009; 284: 16256-16263.
71. Hsiao SJ and Smith S. Tankyrase function at telomeres, spindle poles, and beyond. Biochimie 2008; 90: 83-92.
72. Smith S, Giriat I, Schmitt A and de Lange T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 1998; 282: 1484-1487.
73. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, Hild M, Shi X, Wilson CJ, Mickanin C, Myer V, Fazal A, Tomlinson R, Serluca F, Shao W, Cheng H, Shultz M, Rau C, Schirle M, Schlegl J, Ghidelli S, Fawell S, Lu C, Curtis D, Kirschner MW, Lengauer C, Finan PM, Tallarico JA, Bouwmeester T, Porter JA, Bauer A and Cong F. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009; 461: 614-620.
74. Zhang Y, Liu SM, Mickanin C, Feng Y, Charlat O, Michaud GA, Schirle M, Shi XY, Hild M, Bauer A, Myer VE, Finan PM, Porter JA, Huang SMA and Cong F. RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. Nature Cell Biology 2011; 13: 623-U292.
75. Chen BZ, Dodge ME, Tang W, Lu JM, Ma ZQ, Fan CW, Wei SG, Hao WN, Kilgore J, Williams NS, Roth MG, Amatruda JF, Chen C and Lum L. Small molecule-mediated disruption of Wntdependent signaling in tissue regeneration and cancer. Nature Chemical Biology 2009; 5: 100-107.
76. Lehtio L, Chi NW and Krauss S. Tankyrases as drug targets. FEBS J 2013; 280: 3576-3593.
77. Waaler J, Machon O, von Kries JP, Wilson SR, Lundenes E, Wedlich D, Gradl D, Paulsen JE, Machonova O, Dembinski JL, Dinh H and Krauss S. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Research 2011; 71: 197-205.
78. James RG, Davidson KC, Bosch KA, Biechele TL, Robin NC, Taylor RJ, Major MB, Camp ND, Fowler K, Martins TJ and Moon RT. WIKI4, a novel inhibitor of tankyrase and Wnt/sscatenin signaling. PLoS One 2012; 7: e50457.
79. Voronkov A, Holsworth DD, Waaler J, Wilson SR, Ekblad B, Perdreau-Dahl H, Dinh H, Drewes G, Hopf C, Morth JP and Krauss S. Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor. J Med Chem 2013; 56: 3012-3023.
80. Takada R, Satomi Y, Kurata T, Ueno N, Norioka S, Kondoh H, Takao T and Takada S. Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion. Dev Cell 2006; 11: 791-801.
81. Biechele S, Cox BJ and Rossant J. Porcupine homolog is required for canonical Wnt signaling and gastrulation in mouse embryos. Dev Biol 2011; 355: 275-285.
82. Barrott JJ, Cash GM, Smith AP, Barrow JR and Murtaugh LC. Deletion of mouse Porcn blocks Wnt ligand secretion and reveals an ectodermal etiology of human focal dermal hypoplasia/Goltz syndrome. Proc Natl Acad Sci U S A 2011; 108: 12752-12757.
83. Dodge ME, Moon J, Tuladhar R, Lu J, Jacob LS, Zhang LS, Shi H, Wang X, Moro E, Mongera A, Argenton F, Karner CM, Carroll TJ, Chen C, Amatruda JF and Lum L. Diverse chemical scaffolds support direct inhibition of the membrane-bound O-acyltransferase porcupine. J Biol Chem 2012; 287: 23246-23254.
84. Liu J, Pan SF, Hsieh MH, Ng N, Sun FX, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, Li J, Tompkins C, Pferdekamper A, Steffy A, Cheng J, Kowal C, Phung V, Guo GR, Wang Y, Graham MP, Flynn S, Brenner JC, Li C, Villarroel MC, Schultz PG, Wu X, McNamara P, Sellers WR, Petruzzelli L, Boral AL, Seidel HM, McLaughlin ME, Che JW, Carey TE, Vanasse G and Harris JL. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A 2013; 110: 20224-20229.
85. Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, Cselenyi CS, Jernigan KK, Meyers KC, Hang BI, Waterson AG, Kim K, Melancon B, Ghidu VP, Sulikowski GA, LaFleur B, Salic A, Lee LA, Miller DM 3rd and Lee E. Smallmolecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol 2010; 6: 829-836.
86. Saraswati S, Alfaro MP, Thorne CA, Atkinson J, Lee E and Young PP. Pyrvinium, a potent small molecule Wnt inhibitor, promotes wound repair and post-MI cardiac remodeling. PLoS One 2010; 5: e15521.
87. Venerando A, Girardi C, Ruzzene M and Pinna LA. Pyrvinium pamoate does not activate protein kinase CK1, but promotes Akt/PKB downregulation and GSK3 activation. Biochem J 2013; 452: 131-137.
88. Del Valle-Perez B, Arques O, Vinyoles M, de Herreros AG and Dunach M. Coordinated action of CK1 isoforms in canonical Wnt signaling. Mol Cell Biol 2011; 31: 2877-2888.
89. Cheong JK, Nguyen TH, Wang H, Tan P, Voorhoeve PM, Lee SH and Virshup DM. IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1delta/varepsilon and Wnt/beta-catenin independent inhibition of mitotic spindle formation. Oncogene 2011; 30: 2558-2569.
90. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW and Shivdasani RA. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 2004; 5: 91-102.
91. Gonsalves FC, Klein K, Carson BB, Katz S, Ekas LA, Evans S, Nagourney R, Cardozo T, Brown AM and DasGupta R. An RNAi-based chemical genetic screen identifies three smallmolecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci U S A 2011; 108: 5954-5963.
92. Chen ZC, Venkatesan AM, Dehnhardt CM, Dos Santos O, Delos Santos E, Ayral-Kaloustian S, Chen L, Geng Y, Arndt KT, Lucas J, Chaudhary I and Mansour TS. 2,4-Diamino-quinazolines as inhibitors of beta-catenin/Tcf-4 pathway: Potential treatment for colorectal cancer. Bioorg & Med Chem Lett 2009; 19: 4980-4983.
93. Trosset JY, Dalvit C, Knapp S, Fasolini M, Veronesi M, Mantegani S, Gianellini LM, Catana C, Sundstrom M, Stouten PF and Moll JK. Inhibition of protein-protein interactions: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. Proteins 2006; 64: 60-67.
94. Tian W, Han X, Yan M, Xu Y, Duggineni S, Lin N, Luo G, Li YM, Huang Z and An J. Structurebased discovery of a novel inhibitor targeting the beta-catenin/Tcf4 interaction. Biochemistry 2012; 51: 724-731.
95. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, Schmidt-Wolf IG, Kipps TJ and Carson DA. Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One 2009; 4: e8294.
96. Jin GY, Lu DS, Yao SY, Wu CCN, Liu JX, Carson DA and Cottam HB. Amide derivatives of ethacrynic acid: Synthesis and evaluation as antagonists of Wnt/beta-catenin signaling and CLL cell survival. Bioorg & Med Chem Lett 2009; 19: 606-609.
97. McMillan M and Kahn M. Investigating Wnt signaling: a chemogenomic safari. Drug Discov Today 2005; 10: 1467-1474.
98. Kung AL, Rebel VI, Bronson RT, Ch'ng LE, SieffCA, Livingston DM and Yao TP. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 2000; 14: 272-277.
99. Yamauchi T, Oike Y, Kamon J, Waki H, Komeda K, Tsuchida A, Date Y, Li MX, Miki H, Akanuma Y, Nagai R, Kimura S, Saheki T, Nakazato M, Naitoh T, Yamamura K and Kadowaki T. Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice. Nat Genet 2002; 30: 221-226.
100. Roth JF, Shikama N, Henzen C, Desbaillets I, Lutz W, Marino S, Wittwer J, Schorle H, Gassmann M and Eckner R. Differential role of p300 and CBP acetyltransferase during myogenesis: p300 acts upstream of MyoD and Myf5. EMBO J 2003; 22: 5186-5196.
101. Teo JL, Ma H, Nguyen C, Lam C and Kahn M. Specific inhibition of CBP/beta-catenin interaction rescues defects in neuronal differentiation caused by a presenilin-1 mutation. Proc Natl Acad Sci U S A 2005; 102: 12171-12176.
102. Kahn M. Symmetric division versus asymmetric division: a tale of two coactivators. Future Med Chem 2011; 3: 1745-1763.
103. Hao J, Ao A, Zhou L, Murphy CK, Frist AY, Keel JJ, Thorne CA, Kim K, Lee E and Hong CC. Selective small molecule targeting betacatenin function discovered by in vivo chemical genetic screen. Cell Rep 2013; 4: 898-904.
104. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, Moon RT, Teo JL, Kim HY, Moon SH, Ha JR and Kahn M. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A 2004; 101: 12682-12687.
105. Shah S, Hecht A, Pestell R and Byers SW. Trans-repression of beta-catenin activity by nuclear receptors. J Biol Chem 2003; 278: 48137-48145.
106. Kahn M. Can we safely target the WNT pathway? Nature Reviews Drug Discovery 2014; 13: 513-532.
107. Crosnier C, Stamataki D and Lewis J. Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. Nat Rev Genet 2006; 7: 349-359.
108. Barker N, van de Wetering M and Clevers H. The intestinal stem cell. Genes Dev 2008; 22: 1856-1864.
109. van Es JH, Haegebarth A, Kujala P, Itzkovitz S, Koo BK, Boj SF, Korving J, van den Born M, van Oudenaarden A, Robine S and Clevers H. A Critical Role for the Wnt Effector Tcf4 in Adult Intestinal Homeostatic Self-Renewal. Mol Cell Biol 2012; 32: 1918-1927.
110. Korinek V, Barker N, Moerer P, van Donselaar E, Huls G, Peters PJ and Clevers H. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 1998; 19: 379-383.
111. Fevr T, Robine S, Louvard D and Huelsken J. Wnt/beta-Catenin is essential for intestinal Homeostasis and maintenance of intestinal stem cells. Mol Cell Biol 2007; 27: 7551-7559.
112. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moerer P, van den Born M, Soete G, Pals S, Eilers M, Medema R and Clevers H. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 241-250.
113. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R and Weissman IL. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003; 423: 409-414.
114. Tian H, Biehs B, Warming S, Leong KG, Rangell L, Klein OD and de Sauvage FJ. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 2011; 478: 255-259.
115. Yan KS, Chia LA, Li XN, Ootani A, Su J, Lee JY, Su N, Luo YL, Heilshorn SC, Amieva MR, Sangiorgi E, Capecchi MR and Kuo CJ. The intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. Proc Natl Acad Sci U S A 2012; 109: 466-471.
116. Smith DC, Rosen LS, Chugh R, Goldman JW, Xu L, Kapoun A, Brachmann RK, Dupont J, Stagg RJ, Tolcher AW and Papadopoulos KP. First-inhuman evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway in a phase I study for patients with advanced solid tumors. Journal of Clinical Oncology 2013; 31.
117. El-Khoueiry AB, Ning Y, Yang DY, Cole S, Kahn M, Zoghbi M, Berg J, Fujimori M, Inada T, Kouji H and Lenz HJ. A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. Journal of Clinical Oncology 2013; 31.